Literature DB >> 8825754

Inhibition of HIV-1 expression by HIV-2.

J Rappaport1, S K Arya, M W Richardson, G Baier-Bitterlich, P E Klotman.   

Abstract

HIV-1 and HIV-2 are co-endemic in certain geographic areas. HIV-2 is more weakly pathogenic than HIV-1, and progression to AIDS occurs less frequently and over a longer period of time. Recent epidemiologic studies suggest that individuals infected with HIV-2 have a lower risk of HIV-1 infection. Both immune mechanisms and various modes of viral interference have been proposed to account for these results. Our findings, described in this paper, suggest that HIV-2 inhibits HIV-1 replication. To study the molecular interactions between HIV-1 and HIV-2, proviral clones were transfected alone or in combination into the human T cell line CEM. LTR-CAT indicator constructs were included for the purpose of monitoring viral promoter activity. Viral replication in transfected cells was monitored by p24 antigen capture assay of cell culture supernatants and Western blot analysis of cell extracts. HIV-2 inhibited HIV-1 replication as determined by intracellular and extracellular p24 antigen levels. Similar results were obtained with simultaneous virus infection using HIV-1 and HIV-2, rather than transfections of proviral DNA. Using cotransfection of HIV-1 and HIV-2 LTR indicator gene constructs, the mechanism of inhibition was found to be suppression of the HIV-1 LTR by HIV-2. The inhibitory effect of HIV-2 is not due to Tat-2, but appears to discriminate between the HIV-1 and HIV-2 LTRs based on differences in the Tat activation response element, TAR. These results suggest both a molecular mechanism for HIV-2 interference with HIV-1 replication and a potential molecular approach to therapy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8825754     DOI: 10.1007/bf00196351

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  28 in total

1.  Evolution of human immunodeficiency virus type 1 nef and long terminal repeat sequences over 4 years in vivo and in vitro.

Authors:  S Delassus; R Cheynier; S Wain-Hobson
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

2.  Efficient trans-activation by the HIV-2 Tat protein requires a duplicated TAR RNA structure.

Authors:  B Berkhout; A Gatignol; J Silver; K T Jeang
Journal:  Nucleic Acids Res       Date:  1990-04-11       Impact factor: 16.971

3.  Location of the trans-activating region on the genome of human T-cell lymphotropic virus type III.

Authors:  J Sodroski; R Patarca; C Rosen; F Wong-Staal; W Haseltine
Journal:  Science       Date:  1985-07-05       Impact factor: 47.728

4.  HIV-1 tat trans-activation requires the loop sequence within tar.

Authors:  S Feng; E C Holland
Journal:  Nature       Date:  1988-07-14       Impact factor: 49.962

5.  Human immunodeficiency virus type 2 (HIV-2) trans-activator (Tat): functional domains and the search for trans-dominant negative mutants.

Authors:  S K Arya
Journal:  AIDS Res Hum Retroviruses       Date:  1993-09       Impact factor: 2.205

6.  New human and simian HIV-related retroviruses possess functional transactivator (tat) gene.

Authors:  S K Arya; B Beaver; L Jagodzinski; B Ensoli; P J Kanki; J Albert; E M Fenyo; G Biberfeld; J F Zagury; F Laure
Journal:  Nature       Date:  1987 Aug 6-12       Impact factor: 49.962

7.  Human immunodeficiency virus type 2 long terminal repeat: analysis of regulatory elements.

Authors:  S K Arya; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

8.  Human and simian immunodeficiency retroviruses: activation and differential transactivation of gene expression.

Authors:  S K Arya
Journal:  AIDS Res Hum Retroviruses       Date:  1988-06       Impact factor: 2.205

9.  Virological and polymerase chain reaction studies of HIV-1/HIV-2 dual infection in Côte d'Ivoire.

Authors:  M Peeters; G M Gershy-Damet; K Fransen; K Koffi; M Coulibaly; E Delaporte; P Piot; G van der Groen
Journal:  Lancet       Date:  1992-08-08       Impact factor: 79.321

10.  Molecular characterization of an attenuated human immunodeficiency virus type 2 isolate.

Authors:  P Kumar; H X Hui; J C Kappes; B S Haggarty; J A Hoxie; S K Arya; G M Shaw; B H Hahn
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

View more
  6 in total

1.  The sequence and structure of the 3' arm of the first stem-loop of the human immunodeficiency virus type 2 trans-activation responsive region mediate Tat-2 transactivation.

Authors:  C Browning; J M Hilfinger; S Rainier; V Lin; S Hedderwick; M Smith; D M Markovitz
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

Review 2.  A potentially novel approach for the gene therapy of HIV-1 disease.

Authors:  Z N Berneman
Journal:  J Mol Med (Berl)       Date:  1995-12       Impact factor: 4.599

3.  Potent inhibition of human immunodeficiency virus type 1 (HIV-1) gene expression and virus production by an HIV-2 tat activation-response RNA decoy.

Authors:  C M Browning; L Cagnon; P D Good; J Rossi; D R Engelke; D M Markovitz
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

4.  In vitro correlates of HIV-2-mediated HIV-1 protection.

Authors:  E G Kokkotou; J L Sankale; I Mani; A Gueye-Ndiaye; D Schwartz; M E Essex; S Mboup; P J Kanki
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

5.  HIV-1 outcompetes HIV-2 in dually infected Senegalese individuals with low CD4⁺ cell counts.

Authors:  Dana N Raugi; Geoffrey S Gottlieb; Papa S Sow; Macoumba Toure; Fatima Sall; Awa Gaye; Ibra N'doye; Nancy B Kiviat; Stephen E Hawes
Journal:  AIDS       Date:  2013-09-24       Impact factor: 4.177

6.  Insight into HIV-2 latency may disclose strategies for a cure for HIV-1 infection.

Authors:  Suha Saleh; Lenard Vranckx; Rik Gijsbers; Frauke Christ; Zeger Debyser
Journal:  J Virus Erad       Date:  2017-01-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.